Clinical efficacy of self-designed Chaihu Guizhi Decoction on patients with liver Qi stagnation depression and its effect on tryptophan metabolism pathway induced by inflammatory factors

Start Date14 Jan 2022

Sponsor / Collaborator

First Affiliated Hospital of Guangxi Medical University

100 Clinical Results associated with Chaihu Guizhi Decoction

100 Translational Medicine associated with Chaihu Guizhi Decoction

100 Patents (Medical) associated with Chaihu Guizhi Decoction

Literatures (Medical) associated with Chaihu Guizhi Decoction

25 Mar 2021·Nan fang yi ke da xue xue bao = Journal of Southern Medical University

[Chaihu Guizhi decoction produces antidepressant-like effects via sirt1-p53 signaling pathway].

Article

Author: Ge, X ; Li, J ; Zhu, Z ; Fan, J ; Yuan, L ; Hu, H ; Liu, Y ; Cui, J ; Ren, J ; Cao, X ; Yu, L ; Chen, B ; Zhou, X ; Guo, F ; Lu, C ; Li, S ; Mo, J

OBJECTIVETo investigate the mechanism of the antidepressant-like effects of Chaihu Guizhi decoction (CGD).OBJECTIVEChaihu Guizhi decoction at the daily dose of 17 g/kg and solvent vehicle were administered by gavage in 12 and 14 male C57BL/6J mice for 7 consecutive days, respectively. Forced swimming test (FST), elevated plus maze (EPM) test, open field test (OFT) and novelty-suppressed feeding test (NSF) were performed to assess the depression- and anxiety-like behaviors and motor ability of the mice. We further used chronic social defeat stress (CSDS) and social interaction test to evaluate the antidepressant-like effects of CGD in comparison with the solvent vehicle. Western blotting and RT-qPCR were performed to detect the expressions of sirt1, p53, acetylated p53, and the neuron plasticity-related genes including synapsin I (Syn1), Rab4B, SNAP25 and tubulin beta4b in the hippocampus of the mice.OBJECTIVEIn FST, the immobility time of CGDtreated mice was decreased significantly (P < 0.05); no significant differences were found in the performances in EPM, NSF and OFT tests between the two groups. In social interaction test, the mouse models of CSDS treated with CGD showed significantly increased time in the interaction zone (P < 0.05). Compared with those in the vehicle group, the CGD-treated mouse models exhibited significantly increased protein level of SIRT1 and decreased p53 acetylation (P < 0.05) with up-regulated synapsin I mRNA expression in the hippocampus (P < 0.05); no significant difference were found in Rab (P=0.813), SNAP (P=0.820), or Tubb mRNA expressions (P=0.864) between the two groups.OBJECTIVECGD produces antidepressant-like effects in mice possibly through the sirt1-p53 signaling pathway and synaptic plasticity.

01 Jan 2021·Arerugi = [Allergy]

[A CASE OF REPEATED DRUG-INDUCED LUNG DISEASES DUE TO MULTIPLE HERBAL MEDICINES CONTAINING COMMON INGREDIENTS].

Article

Author: Nakamura, Shogo ; Ikeda, Masaki ; Morita, Meiko ; Kusagaya, Hideki ; Oyama, Yoshiyuki ; Mori, Rie ; Takuma, Sho

We present a rare case of repetitive lung disease caused by various herbal medicines containing common ingredients. In June 201X-2, an 81-year-old man with chronic sinusitis was treated with Shini-seihai-to. One month later, the patient experienced liver dysfunction, and pulmonary opacity was observed on a chest radiograph; this condition improved following the discontinuation of Shini-seihai-to. In October 201X-2, the patient developed fever and dyspnea after treatment with Saiko-keishi-to, which was administered to treat irritable bowel syndrome, and was diagnosed with pneumonia. His condition did not improve with antimicrobial treatment but did improve with systemic corticosteroids. Following discharge from the hospital, the patient took both Shini-seihai-to and Hochu-ekki-to. He developed a fever two days later, which improved after discontinuing the medicines. The patient developed a cough after taking Sairei-to in February 201X and was subsequently admitted to our hospital with respiratory failure; pulmonary opacity was observed on a chest computed tomography scan. On the basis of clinical course, lymphocytosis in bronchoalveolar lavage fluid, and drug-induced lymphocyte stimulation tests, we diagnosed the patient with Sairei-to-induced lung disease. The patient's condition improved after discontinuing Sairei-to. We conclude that common ingredients in different herbal medicines may cause drug-induced lung injury. Therefore, we recommend that scrupulous attention should be paid to Chinese herbal medicine use in patients with a history of lung injury induced by herbal medicines.

01 Nov 2014·Journal of Integrative MedicineQ2 · MEDICINE

Effect of Saikokeishito, a Kampo medicine, on hydrogen peroxide-induced premature senescence of normal human dermal fibroblasts

Q2 · MEDICINE

Article

Author: Tomosugi, Naohisa ; Takata, Takanobu ; Motoo, Yoshiharu

OBJECTIVESaikokeishito (TJ-10) is a Kampo (traditional Japanese herbal) medicine, clinically used for hundreds of years in East Asia. Among its various mechanisms elucidated so far, TJ-10 inhibits the production of transforming growth factor-β1 (TGF-β1) and development of pancreatic fibrosis in vivo. Oxidative damage of normal human dermal fibroblasts (NHDFs) in the corium is a cause of human dermal senescence. Our aim was to determine whether TJ-10 protects NHDFs from premature senescence by hydrogen peroxide (H₂O₂).METHODSPremature senescence was induced in NHDFs by 200 μmol/L H₂O₂ for 4 h. Cell viability and the expressions of p53, AMP-activated protein kinase α1 (AMPKα1), AMPKα2, and 14-3-3 protein sigma (14-3-3 σ) were measured in NHDFs treated with TJ-10 for 48 h before exposure to H₂O₂for 4 h.RESULTSCell viability after treatment with 200 μmol/L H₂O₂ for 4 h was similar (about 80%) to after pre-treatment with TJ-10. Ascorbic acid as a control did not protect NHDFs from damage by 200 μmol/L H₂O₂. Treatment with 200 μmol/L H₂O₂tended to up-regulate p53 and to down-regulate SIRT1 and AMPKα1, but had no effect on AMPKα2 and 14-3-3 σ expression. Pretreatment with TJ-10 inhibited H₂O₂-induced up-regulation of p53 and enhanced AMPKα1 expression.CONCLUSIONIt is suggested that Saikokeishito has a protective effect on oxidative stress-induced senescence of NHDFs.

100 Deals associated with Chaihu Guizhi Decoction

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cholecystitis	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Enteritis	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Fever	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Gastralgia	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Gastritis	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Headache	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Hyperchlorhydria	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Nausea	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Neuralgia	JP	Ohsugi Pharmaceutical Co., Ltd.	22 Aug 1986
Common Cold	JP	Kracie Pharmaceutical Ltd.	24 Jun 1986
Gastroenteritis	JP	Kracie Pharmaceutical Ltd.	24 Jun 1986

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Chaihu Guizhi Decoction

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation